101 related articles for article (PubMed ID: 21670604)
41. Distinct pattern of allelic loss and inactivation of cadherin 1 and 5 genes in mammary carcinomas arising in p53(+/-) mice.
Umesako S; Iiga S; Takahashi M; Imura K; Mori N; Hong DP; Song CW; Niwa O; Okumoto M
J Radiat Res; 2007 Mar; 48(2):143-52. PubMed ID: 17327688
[TBL] [Abstract][Full Text] [Related]
42. ATF-2 controls transcription of Maspin and GADD45 alpha genes independently from p53 to suppress mammary tumors.
Maekawa T; Sano Y; Shinagawa T; Rahman Z; Sakuma T; Nomura S; Licht JD; Ishii S
Oncogene; 2008 Feb; 27(8):1045-54. PubMed ID: 17700520
[TBL] [Abstract][Full Text] [Related]
43. Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice.
Backlund MG; Trasti SL; Backlund DC; Cressman VL; Godfrey V; Koller BH
Cancer Res; 2001 Sep; 61(17):6577-82. PubMed ID: 11522657
[TBL] [Abstract][Full Text] [Related]
44. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.
Xu X; Wagner KU; Larson D; Weaver Z; Li C; Ried T; Hennighausen L; Wynshaw-Boris A; Deng CX
Nat Genet; 1999 May; 22(1):37-43. PubMed ID: 10319859
[TBL] [Abstract][Full Text] [Related]
45. Intratumoral heterogeneity in microsatellite alterations in BRCA1 and PTEN regions in sporadic colorectal cancer.
Garcia JM; Rodriguez R; Silva J; Muñoz C; Dominguez G; Silva JM; Carcereny E; Provencio M; España P; Bonilla F
Ann Surg Oncol; 2003 Oct; 10(8):876-81. PubMed ID: 14527905
[TBL] [Abstract][Full Text] [Related]
46. The Cytoskeletal Adapter Protein Spinophilin Regulates Invadopodia Dynamics and Tumor Cell Invasion in Glioblastoma.
Cheerathodi M; Avci NG; Guerrero PA; Tang LK; Popp J; Morales JE; Chen Z; Carnero A; Lang FF; Ballif BA; Rivera GM; McCarty JH
Mol Cancer Res; 2016 Dec; 14(12):1277-1287. PubMed ID: 27655131
[TBL] [Abstract][Full Text] [Related]
47. Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.
Shetzer Y; Napchan Y; Kaufman T; Molchadsky A; Tal P; Goldfinger N; Rotter V
Int J Cancer; 2017 Mar; 140(6):1364-1369. PubMed ID: 28008605
[TBL] [Abstract][Full Text] [Related]
48. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent.
French JE; Lacks GD; Trempus C; Dunnick JK; Foley J; Mahler J; Tice RR; Tennant RW
Carcinogenesis; 2001 Jan; 22(1):99-106. PubMed ID: 11159747
[TBL] [Abstract][Full Text] [Related]
49. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
Xing D; Orsulic S
Cancer Res; 2006 Sep; 66(18):8949-53. PubMed ID: 16982732
[TBL] [Abstract][Full Text] [Related]
50. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
51. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Becker K; Goldberg M; Helmbold P; Holbach LM; Loeffler KU; Ballhausen WG
Br J Dermatol; 2008 Dec; 159(6):1282-9. PubMed ID: 18717684
[TBL] [Abstract][Full Text] [Related]
52. In vivo analysis of mammary and non-mammary tumorigenesis in MMTV-cyclin D1 transgenic mice deficient in p53.
Hosokawa Y; Papanikolaou A; Cardiff RD; Yoshimoto K; Bernstein M; Wang TC; Schmidt EV; Arnold A
Transgenic Res; 2001 Oct; 10(5):471-8. PubMed ID: 11708657
[TBL] [Abstract][Full Text] [Related]
53. Ovarian carcinoma in situ with germline BRCA1 mutation and loss of heterozygosity at BRCA1 and TP53.
Werness BA; Parvatiyar P; Ramus SJ; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; DiCioccio RA; Wiest J; Tsukada Y; Ponder BA; Piver MS
J Natl Cancer Inst; 2000 Jul; 92(13):1088-91. PubMed ID: 10880552
[TBL] [Abstract][Full Text] [Related]
54. Evidence for two tumor suppressor loci associated with proximal chromosome 9p to q and distal chromosome 9q in bladder cancer and the initial screening for GAS1 and PTC mutations.
Simoneau AR; Spruck CH; Gonzalez-Zulueta M; Gonzalgo ML; Chan MF; Tsai YC; Dean M; Steven K; Horn T; Jones PA
Cancer Res; 1996 Nov; 56(21):5039-43. PubMed ID: 8895761
[TBL] [Abstract][Full Text] [Related]
55. Female embryonic lethality in mice nullizygous for both Msh2 and p53.
Cranston A; Bocker T; Reitmair A; Palazzo J; Wilson T; Mak T; Fishel R
Nat Genet; 1997 Sep; 17(1):114-8. PubMed ID: 9288110
[TBL] [Abstract][Full Text] [Related]
56. Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.
Karabinis ME; Larson D; Barlow C; Wynshaw-Boris A; Moser AR
Carcinogenesis; 2001 Feb; 22(2):343-6. PubMed ID: 11181458
[TBL] [Abstract][Full Text] [Related]
57. Mouse models in tumor suppression.
Ghebranious N; Donehower LA
Oncogene; 1998 Dec; 17(25):3385-400. PubMed ID: 9917000
[TBL] [Abstract][Full Text] [Related]
58. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.
Mao JH; Perez-Losada J; Wu D; Delrosario R; Tsunematsu R; Nakayama KI; Brown K; Bryson S; Balmain A
Nature; 2004 Dec; 432(7018):775-9. PubMed ID: 15592418
[TBL] [Abstract][Full Text] [Related]
59. Knockout mouse models and mammary tumorigenesis.
Deng CX; Brodie SG
Semin Cancer Biol; 2001 Oct; 11(5):387-94. PubMed ID: 11562181
[TBL] [Abstract][Full Text] [Related]
60. Somatic allelic loss at the DCC, APC, nm23-H1 and p53 tumor suppressor gene loci in human prostatic carcinoma.
Brewster SF; Browne S; Brown KW
J Urol; 1994 Apr; 151(4):1073-7. PubMed ID: 7510345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
